Jefferies Downgrades AstraZeneca to Hold
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Peter Welford has downgraded AstraZeneca (NASDAQ:AZN) from Buy to Hold, indicating a more cautious outlook on the stock.
January 03, 2024 | 11:35 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AstraZeneca's stock rating has been downgraded by Jefferies from Buy to Hold, suggesting potential stagnation or uncertainty in the stock's near-term performance.
Downgrades by analysts can lead to a neutral or negative perception among investors, potentially causing short-term stagnation or a slight decrease in the stock price. However, the change from Buy to Hold is not as severe as a sell recommendation, which is why the score is neutral.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100